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Abstract
Aims: Septic shock, the severe form of sepsis, is associated with development of progressive damage in multiple 
organs. Kidney can be injured and its functions altered by activation of coagulation, vasoactive-peptide and 
inflammatory processes in sepsis. Endothelin (ET)-1, a potent vasoconstrictor, is implicated in the pathogenesis of 
sepsis and its complications. Protease-activated receptors (PARs) are shown to play an important role in the 
interplay between inflammation and coagulation. We examined the time-dependent alterations of ET-1 and 
inflammatory cytokine, such as tumor necrosis factor (TNF)-α in kidney tissue in lipopolysaccharide (LPS)-induced 
septic rat model and the effects of PAR2 blocking peptide on the LPS-induced elevations of renal ET-1 and TNF-α 
levels.
Main methods: Male Wistar rats at 8 weeks of age were administered with either saline solution or LPS at different 
time points (1, 3, 6 and 10 h). Additionally, we treated LPS-administered rats with PAR2 blocking peptide for 3 h to 
assess whether blockade of PAR2 has a regulatory role on the ET-1 level in septic kidney. Key findings: An increase 
in ET-1 peptide level was observed in kidney tissue after LPS administration time-dependently. Levels of renal TNF-
α peaked (around 12-fold) at 1 h of sepsis. Interestingly, PAR2 blocking peptide normalized the LPS-induced 
elevations of renal ET-1 and TNF-α levels.
Significance: The present study reveals a distinct chronological expression of ET-1 and TNF-α in LPS-administered 
renal tissues and that blockade of PAR2 may play a crucial role in treating renal injury, via normalization of 
inflammation, coagulation and vaso-active peptide.
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vasodilation in the systemic circulation, based on the disruption of the
overall balance between vasodilation and vasoconstriction in the kid-
ney. Endothelin-1 (ET-1) is the most potent vasoconstrictor peptide
known so far (Yanagisawa et al., 1988) and LPS stimulates its synthesis
and release in cultured endothelial cells (Marsden and Brenner, 1992;
Nakamura et al., 1991) and is also known to significantly elevate
its plasma levels in experimental animals (Nakamura et al., 1991;
Pernow et al., 1990; Sugiura et al., 1989; Vemulapalli et al., 1991) and
patients with septic shock (Pittet et al., 1991; Takakuwa et al., 1994;
Voerman et al., 1992;Weitzberg et al., 1991). The possible involvement
of the ET-1 system in human septic shock is further supported by a clear
correlation between ET-1 plasma levels and morbidity and mortality of
septic patients (Brauner et al., 2000;Hartemink et al., 2001). However, it
is still controversial whether elevated plasma ET-1 levels aremarkers of
endothelial dysfunction/damage or mediators of the disease. Increased
systemic and/or local production of ET-1 has been implicated in blood
pressure elevation (Gardiner et al., 1995; Ruetten et al., 1996), media-
tion of renal vasoconstriction and failure (Pernow et al., 1990), and
also in pulmonary and portal hypertension during endotoxic shock
(Yamamoto et al., 1997). Clearly, ET-1 system is likely involved in
renal complications during sepsis. Accordingly, recently we reported
that ET-1 level in kidney tissue is increased time-dependently after
LPS administration with a higher plasma ET-1 level (Yamaguchi et al.,
2006).
Protease-activated receptors (PARs), members of a recently de-
scribed family of G-protein-coupled, seven-transmembrane-domain re-
ceptors, are activated through proteolytic cleavage of their N-terminal
domain by proteinases, resulting in the generation of a new
N-terminal “tethered ligand”, which can auto activate the receptor
function (Ossovskaya and Bunnett, 2004). Four members of the PAR
family have been cloned. PAR1, PAR3, and PAR4 can be activated by
thrombin, and PAR2 can be activated by trypsin,mast cell tryptase, neu-
trophil proteinase 3, tissue factor/factor VIIa/factor Xa, and membrane-
tethered serine proteinase-1 (Lourbakos et al., 2001; Vergnolle et al.,
2001a). The involvement of PAR2 in inflammation is supported by
several studies. Early studies reported that PAR2 expression was up-
regulated by inflammatory mediators such as TNF-α, IL-1 and LPS
(Nystedt et al., 1996). Moreover, a number of studies have demon-
strated that activation of PAR2 can lead to blood vessel relaxation,
hypotension, increased vascular permeability, granulocyte infiltra-
tion, leukocyte adhesion and margination, and pain (Cocks and
Moffatt, 2000; Coughlin and Camerer, 2003; Vergnolle et al.,
2001b) — all effects that encounter for the cardinal signs of inflamma-
tion. Recently, the role of PAR2 in the pathogenesis of sepsis has
begun to be appreciated. A combination of thrombin inhibition and
PAR2 deficiency reduced inflammation and mortality in a mouse
model of endotoxemia (Pawlinski et al., 2004). We have also demon-
strated that the blockade of PAR2 ameliorates liver injury via the nor-
malization of the inflammation, coagulation and fibrinolytic pathways
(Jesmin et al., 2006).
In the kidney, PAR2 expression has been reported in collecting duct
cells, mesangial cells, interstitial fibroblasts, vascular endothelial cells
andproximal tubule cells (Coughlin, 2000; Vesey et al., 2007). Thepresent
study intended to use a PAR2 blocking peptide to LPS-administered
endotoxemic rats to investigate whether PAR2 blockade would have
any role on the upregulated ET-1, TNF-α and iNOS levels in kidney tissues.
Materials and methods
Animals and treatments
In the first series of our study, endotoxemia was induced by admin-
istering a single (2ml) intra-peritoneal injection of LPS (in sterile saline
solution) derived from Escherichia coli 055:B5 (15 mg/kg body weight)
to adult male Wistar rats. The animals were killed in groups using
pentobarbital (80 mg/kg body weight intraperitoneal [ip]) at differenttime points after LPS administration (1, 3, 6, and 10 h, n = 30 rats/
group). The control group received an equal volume of sterile saline
(2 ml/rat) containing no LPS. Whole kidney tissues were carefully har-
vested, immediately frozen in liquid nitrogen, and stored at −80 °C.
For the paraffin section preparations, after the kidney tissues were har-
vested, they were postfixed in 4% paraformaldehyde overnight and
processed routinely for paraffin embedding. All experimental proce-
dures in the present study were performed in accordance with the
institutional guidelines of the University of Tsukuba Graduate School
of Medicine Animal Care and Use Committee.
In the second part of the study, in order to investigate the specific
role of PAR2 in the LPS-induced elevated ET-1 peptide level in the
kidney, the PAR2 blocking peptide (BP) was used to treat the rats in
addition to LPS. For this purpose, some rats were anesthetizedwith ure-
thane (35% ethyl carbamate [Wako Pure Chemical Industries, Osaka,
Japan] + 4% alpha-chloralose [Wako] saline solution wt./vol., 0.4 to
0.8 g/kg, ip), and the left jugular vein was cannulated for drug adminis-
tration. All drugs being tested were administered intravenously as a
slowbolus injection. LPS (15 mg/kg, intravenous [iv])was administered
through the jugular vein for 3 h (n = 20). Thirty minutes (min) before
LPS administration, the PAR2 BP (sc-9278 P, Santa Cruz Biotechnology,
Santa Cruz, CA) treated groupwas administered PAR2 BP intravenously
as a slow bolus injection (100 μg/kg, 500 μl/kg PBS) and PAR2 BP was
continuously infused (20 μ/kg/h, 100 μl PBS/h) through the jugular
vein with a pump for 3 h (n = 20). Non-treated rats were used as a
control (n = 20).
Measurements of hemodynamic and biochemical parameters
On the day of the experiment, the rats were anesthetized with pen-
tobarbital sodium (40 mg/kg body weight ip) and a microtip pressure
transducer catheter (SPC-320, Millar Instruments, Houston, TX, USA)
was inserted into the left carotid artery. The arterial blood pressure
and heart rate were monitored with a pressure transducer (model
SCK-590, Gould, OH, USA) and recorded using a polygraph system
(amplifier, AP-601G; Tachometer, AT-601G; thermal-pen recorder,
WT-687G; Nihon Kohden, Tokyo, Japan). Thereafter, plasma and
serum samples were prepared. In preparing the plasma samples, the
proportion of blood to the sodium citrate dehydrate anticoagulant
volume was 9:1. Serum creatinine levels and blood urea nitrogen
(BUN) were measured using kits from Wako Pure Chemical Industries,
LTD (Osaka, Japan).
Histopathological examination
For thehistopathological analysis, the tissue specimenswerefixed in
a 4% buffered formalin solution, dehydrated through an ethanol series,
embedded in paraffin, and sliced into 5-μm-thick sections. After
deparaffinization, the sections were stained with hematoxylin and
eosin (HE) using the standard histological method.
TNF-α and iNOS immunoassays
TNF-α levels in the serum and kidney tissue specimenswere detect-
ed using a rat TNF-α enzyme-linked immunosorbent assay (ELISA) kit
(R and D Systems, Minneapolis, MN). This assay employs the quantita-
tive sandwich enzyme immunoassay technique. Amonoclonal antibody
specific for rat TNF-α has been pre-coated onto amicroplate. Standards,
controls, and samples are pipetted into the wells and any rat TNF-α
present is bound by the immobilized antibody. After washing away
any unbound substances, an enzyme-linked polyclonal antibody specif-
ic for rat TNF-α is added to the wells. Following a wash to remove any
unbound antibody-enzyme reagent, a substrate solution is added to
the wells. The enzyme reaction yields a blue product that turns yellow
when the Stop Solution is added. The intensity of the color measured
is in proportion to the amount of rat TNF-α bound in the initial step.
The sample values are then read off the standard curve. For iNOS, we
used a Human iNOS Immunoassay kit (R and D Systems, Minneapolis,
MN).
Enzyme immunoassay for plasma and renal ET-1 levels
Concentration of ET-1 in plasma and renal tissue extracts was deter-
mined using an ET-1 Enzyme Immuno Assay Kit (Immuno-Biological
Laboratories, Fujioka, Japan). This kit is a solid phase sandwich ELISA
using 2 kinds of high specific antibodies. Tetraethyl Benzidine (TMB)
is used as a coloring agent (Chromogen), the strength of which is in pro-
portion to the quantities of ET-1. In plasma and kidney tissue extracts,
an equal volume of 0.1% trifluoroacetic acid (TFA) in water was added.
Then, the samplewas centrifuged at 3000 ×g for 15min at 4 °C to clarify
and the supernatant was saved. After a 200 mg C 18 Sep-Pak column
(Waters Inc. Part No. 235D1) waswashed with 4 × 1ml of 60% acetoni-
trile in 0.1% TFA followed by 4 × 5ml of 0.1% TFA in water, the superna-
tant was applied to the column andwashedwith 4 × 5ml of 0.1% TFA in
water. The sample was eluted slowly by applying 3 × 1 ml of 60%
acetonitrile in 0.1% TFA inwater and the eluantwas collected in a plastic
tube. The eluant was then evaporated to dryness using a centrifugal
concentrator under vacuum. The sample was reconstituted with assay
buffer and measured immediately according to the manufacturer's
instructions.
Statistical analysis
Results are expressed asmean± S.E., and the sample number equals
the number of animals in each group. Means were compared by one
factor analysis of variance, followed by the Scheffé's test for multiple
comparisons. Differences were considered significant at p b 0.05.
Results
Effects of LPS on hemodynamic and biochemical parameters (Table 1)
Both the systolic and diastolic blood pressures significantly de-
creased at different time points after LPS administration compared to
control rats (Table 1). Levels of serum iNOS (a crucial inflammatoryme-
diator) increased significantly after LPS administration, peaking at 1 h
(more than 3-fold increase compared to control group) andmaintained
at significantly higher levels during all the time points following LPS
administration (Table 1). The serum levels of TNF-α (another potential
inflammatory cytokine), as determined by ELISA, were elevated after
administration of LPS (Table 1), reaching their peak levels at 1 h
(1200-fold from control), but decreasing thereafter. Thus, from the
present study, it is obvious that serum levels of potential inflammatory
mediators were much more elevated at circulatory level during the
early hours of endotoxemic induction. Furthermore, immunoreactive
ET-1 levels in plasma were significantly higher following LPS adminis-
tration for all time points, reaching peak levels at 3 h after LPSTable 1
Effects of LPS on hemodynamic and biochemical parameters.
LPS
Control 1 h
Systolic BP (mm Hg) 132 ± 5 121 ± 4⁎
Diastolic BP (mm Hg) 87 ± 4 75 ± 3⁎
iNOS (serum, U/ml) 7.8 ± 1.0 25.1 ± 3.6 ⁎⁎
ET-1 (plasma, pg/ml) 0.8 ± 0.4 8.2 ± 2.0⁎⁎
TNF-α (serum, pg/ml) 23 ± 2 2340 ± 340⁎⁎
BUN (serum, mg/dl) 20.2 ± 1.6 22.1 ± 1.3
Creatinine (serum, mg/dl) 0.8 ± 0.1 1.3 ± 0.1⁎
LPS, lipopolysaccharide; BP, blood pressure; iNOS, inducible nitric oxide synthase; TNF-α, tum
⁎ p b 0.05 vs control.
⁎⁎ p b 0.01 vs control.administration. Further, serum creatinine levels increased during all
the time points after LPS administration. In contrast, levels of the
serumBUNbegan to increase significantly only 3 h after LPS administra-
tion. Both levels of serum creatinine and BUN (important parameters of
kidney function) exhibited a time-dependent-like increasing trends
after LPS administration.Histopathology after LPS administration
Evaluation of renal histology of H&E-stained tissue sections showed
no evidence of intra-glomerular thrombosis and/or disseminated intra-
vascular coagulation in any of the treated animals (Fig. 1). Besides, these
sections showed only minimal tubular degenerative changes; that is,
focal tubular dilatation with mild swelling or thinning of the epithelial
cells at 3 h after LPS administration (Fig. 1). These findings are consis-
tent with a septic kidney.Effects of PAR2 blocking on serum creatinine and BUN levels
The elevated serum levels of both creatinine (1.42± 0.11 mg/dl) and
BUN (34.70 ± 2.80 mg/dl) in LPS-treated rats at 3 h were almost un-
changed (creatinine, 1.37 ± 0.13 mg/dl; BUN, 37.50 ± 3.20 mg/dl) after
the administration of PAR2 BP to the LPS-treated rats (Fig. 2A and B),
respectively. These results suggest that PAR2 BP failed to reverse the im-
portant parameters of kidney function in LPS-induced endotoxemic rats.Effects of blocking PAR2 on serum and renal levels of TNF-α
The elevated levels of serum TNF-α (710.00 ± 55.00 pg/ml) in LPS-
administered rats were significantly normalized at 3 h of endotoxemia
after blocking PAR2 (290.00 ± 38.00 pg/ml) (Fig. 2C). At 1 h, the
amount of TNF-α in renal tissue, as determined by ELISA (Fig. 3A),
was significantly elevated compared to control group in the LPS-
treated animals (about 17-fold increase) and thereafter declined. Thus,
levels of renal TNF-α increased significantly in the early hours following
LPS administration (Fig. 3A) and were remarkably normalized (more
than 50% reversal) by PAR2 blockade for 3 h (Fig. 3B).Effects of PAR2 blocking on renal levels of iNOS
iNOSprotein expressionwas induced during all the time-points after
LPS administration compared to control rats in renal tissues, as deter-
mined by ELISA (Fig. 3C), peaking at 3 h after LPS injection. A 60%
increase in renal iNOS protein expression was noted at 3 h after LPS ad-
ministration (Fig. 3C) compared to control tissues. Treatmentwith PAR2
BP for 3 h greatly normalized the elevated levels of iNOS in renal tissues
of LPS-administered rats {Control (0.97 ± 0.11 U/mg): LPS (1.65 ±
0.17 U/mg): LPS + PAR2 BP (1.27 ± 0.12 U/mg)}, respectively.3 h 6 h 10 h
111 ± 5⁎⁎ 102 ± 5⁎⁎ 114 ± 7⁎⁎
73 ± 4⁎ 72 ± 5⁎ 76 ± 4⁎
17.3 ± 3.1⁎ 11.4 ± 2.1⁎⁎ 11.5 ± 0.5⁎⁎
23.4 ± 9.9⁎⁎ 9.4 ± 6.0⁎ 4.8 ± 1.9⁎
512 ± 32⁎ 125 ± 11⁎ 81 ± 7⁎
36.7 ± 3.3⁎ 46.4 ± 7.2⁎ 72.5 ± 9.3⁎
1.4 ± 0.1⁎ 1.6 ± 0.1⁎ 1.5 ± 0.1⁎
or necrosis factor-α; BUN, blood urea nitrogen; ET-1, endothelin-1.
Fig. 1.Morphological findings by hematoxylin and eosin staining in the kidney tissues in control rats (A) and 3 h after lipopolysaccharide (LPS) administration (B). Magnification, 100×.Effects of blocking PAR2 on levels of plasma and renal tissue ET-1
A time-dependent increase in levels of renal ET-1 peptidewas noted
in LPS-administered compared to the control group (Fig. 4A). Further,
after the 3 h time point, ET-1 levels were significantly higher in LPS ad-
ministered rats compared to the corresponding control group. Ten
hours (10 h) after LPS administration, a 4.5-fold increase in ET-1 level
was observed (Fig. 4A) in LPS administered renal tissues compared to
the control group. Treatmentwith PAR2 BP for 3 h significantly normal-
ized the upregulated ET-1 level in renal tissues of LPS-administered rats
{Con (0.90 ± 0.10 pg/mg): LPS (3.50 ± 0.30 pg/mg): LPS + PAR2 BP
(1.80 ± 0.20 pg/mg)}, respectively.
Discussion
The present study demonstrates that the levels of ET-1 peptide in-
creased in kidney tissues after LPS administration time-dependently
with a rise in plasma ET-1 concentration compared to control rats.
These increases in renal and plasma ET-1 levels were associated with
a rise in TNF-α and iNOS. Both the systolic and diastolic blood pressures
significantly decreased in LPS-administered rats. The present study is
the first time to demonstrate that blockade of PAR2 could reduce
elevation of renal ET-1 as well as TNF-α and iNOS in LPS-induced
endotoxemic rats without affecting the circulatory levels of renal
function parameters, such as creatinine and BUN.
We show here significant increases in levels of serum creatinine and
BUN after LPS administration, indicating impairment of kidney function
in the endotoxemicmodels used in the present study. Regarding the his-
tological injury in the renal tissues, minimal injury was seen at 3 h after
LPS administration, consistentwith our previous study (Yamaguchi et al.,
2006). Further, we also show here, usingWistar rats, that blood pressure
continued to decrease even at 10 h after LPS administration, although theFig. 2. Effects of PAR2BPon serum(A) creatinine, (B) BUN and (C) TNF-α levels from the control
3 h.extent of decrease was not abrupt and remarkable. It is possible that it
may be the reason why therewere no remarkable histological chang-
es in renal tissues after LPS administration. Thus, collectively, the
endotoxemic models used in the present study had impairment of
renal function parameters, minimal morphological injury in kidney as
well as decrease of systemic blood pressure.
The models used in the present study showed increase in levels of
inflammatory cytokines such as TNF-α and iNOS. Further, consistent
with our previous studies (Jesmin et al., 2004, 2006, 2007) and earlier
reports from other labs (Cohen, 2002; Norman et al., 1995; Putensen
and Wrigge, 2000), increase in levels of plasma TNF-α was noted in
the earlier hours of endotoxemia. The pathogenic role of TNF-α in
endotoxemic renal failure has been suggested. For example, an intrave-
nous infusion of TNF-α in rabbits or perfusion of isolated rat kidneywith
TNF-α led to a decrease in glomerular filtration rate (GFR) (Bertani
et al., 1989; Van der Veen et al., 1999). In rabbits, an intravenous infu-
sion of TNF-α induced glomerular fibrin deposition and renal failure
(Bertani et al., 1989). In the present study, we found elevated levels of
TNF-α after LPS administration in kidney tissues, meaning that the ele-
vated levels of TNF-αwould possibly be involved in the pathogenesis of
LPS-induced renal dysfunction. Similarly, consistent to our previous
study (Yamaguchi et al., 2006), we also show here elevated levels of cir-
culatory and renal iNOS after LPS administration. Various inflammatory
stimuli, such as LPS and proinflammatory cytokines, stimulate the
endogenous NO production by activation of iNOS (Feihl et al., 2001). A
local induction of iNOS, which is constitutively expressed in the kidney,
in particular in the medulla and proximal tubules, may be the cause of
peroxynitrite-related tubular injury as a result of local formation of
reactive oxygen and nitrogen species during systemic inflammation
(Ortiz and Garvin, 2003).
Consistent with our previous study (Yamaguchi et al., 2006) in the
current investigation also we found a time-dependent increase in ET-1and LPS-treated rats. Values aremean±S.E. (n=22). *pb 0.01 vs control, #p b 0.01 vs LPS
Fig. 3. (A, C) Renal levels of TNF-α and iNOS from the control and LPS-treated rats. TNF-α and iNOSweremeasured by ELISA. Values aremean± S.E. (n=22). *p b 0.01with respect to the
control. (B, D) Effects of PAR2 BP on renal TNF-α and iNOS levels at 3 h after LPS administration. Values are mean ± S.E. (n = 22). *p b 0.01 vs control, #p b 0.01 vs LPS 3 h.peptide level after LPS administration in renal tissues. In fact, the role of
ET-1 in renal complications in sepsis is recently being investigated. ET-1
receptor blockade is useful in preventing albumin escape during endo-
toxin shock in conscious, chronically catheterized rats (Filep et al.,
1995). Moreover, others have shown that ET-1 receptor antagonist
prevented LPS-induced metabolic acidosis and hypoxemia, and im-
proved LPS-induced decreases in urine volume, renal blood flow, creat-
inine clearance, and urine osmolality (Mitaka et al., 1999). The fact that
LPS induces expression of both renal ET type A (ETA) and ET type B (ETB)
receptors, as shown in our previous study (Yamaguchi et al., 2006) indi-
cates that dual ET-1 antagonism could prove useful in preventing renal
dysfunction in septicmodel. Although the precisemechanisms underly-
ing the expression pattern of these molecules are presently unclear,
based on the findings of the present and previous studies, we speculate
that increased levels of ET-1 are triggered by compensatory mecha-
nisms aimed at counteracting the undesirable effects generated by
abnormally high levels of NO/iNOS. In fact, the early renal dysfunction
of endotoxemia results from renal hypoperfusion caused mainly by an
imbalance in renal vasoconstrictors and vasodilators (Knotek et al.,
2001).Fig. 4. (A) Renal level of ET-1 from the control and LPS-treated rats. ET-1wasmeasured by ELISA
BP on renal ET-1 level at 3 h after LPS administration. Values are mean ± S.E. (n = 22). *p b 0Themost crucial findings of the present study are the demonstration
of effects of PAR2 BP on various circulatory parameters from inflamma-
tory cytokines to renal functions. Although PAR2 BP significantly altered
levels of plasma TNF-α, PAR2 BP had no observable effects on serum
creatinine and BUN levels. In IgA nephropathy, a positive association be-
tween PAR2 positive cells in kidney and serum creatinine level has been
previously reported (Liu et al., 2010). This is in contrastwith the current
findings where PAR2 BP was found to be ineffective to reverse the
upregulated levels of important kidney function parameters, such as
creatinine and BUN in endotoxemic rat. It is important to state here
that the morphological injury at 3 h endotoxemic rat was minimal and
we assume that PAR2 BP has the potential in normalizing the alteration
of inflammatory cytokine such as TNF-αwithout altering the renalmor-
phology aswell as circulatory parameters of renal function. This conclu-
sion is consistent with the fact that the regulatory effects of PAR2 on
TNF-α expression have been documented inmany studies. For instance,
PAR2 directly regulates TNF-α expression in coronary microcirculation
in type 2 diabetes (Park et al., 2011). Kim et al. (2002) reported that
PAR2 agonist induces TNF-α secretion through the activation of extra-
cellular signal-regulated kinase (ERK) and p38 mitogen-activated. Values aremean± S.E. (n= 20). *p b 0.01with respect to the control. (B) Effects of PAR2
.01 vs control, #p b 0.01 vs LPS 3 h.
protein kinases (MAP kinase) in atrocytoma cells (Kim et al., 2002;
Kleinbongard et al., 2010). Future studies should focus on the effects
of PAR2 BP on above signal transduction in the current experimental
setting.
PAR2 may contribute to LPS-mediated organ dysfunction not only
through the inflammatory cytokine, but also through vasoconstrictive
peptides like ET-1. In the present study, we found that blockade of
PAR2 significantly suppressed the renal ET-1 level. This suppression of
ET-1 by PAR2 blockade may involve TNF and NO pathways. Studies
have demonstrated that TNF-α can induce ET-1 expression. TNF-α
increases the transcription of ET-1 gene (Miyauchi and Masaki, 1999).
NF-kappa B functions as one of main regulatory factors in TNF-α-
induced ET-1 gene transcription. In cultured endothelial cells, TNF-α
exposure resulted in an increased secretion of ET-1 (Corder et al.,
1995) which was accompanied by a corresponding increase in prepro-
ET-1 mRNA transcript levels (Marsden and Brenner, 1992). We specu-
late that, ET-1 might be an important mediator of TNF-α-induced
renal dysfunction after LPS administration although the detailed mech-
anistic insights remain to be explored. And PAR2 may one of the key
molecules regulating TNF-α production in sepsis. Accordingly, in the
present study we found that blockade of PAR2 lowers both the plasma
and renal TNF-α levels. More recently, we showed that blockade of
PAR2 significantly improves LPS-induced acute liver injury through
the suppression of TNF-α and coagulation system (Jesmin et al.,
2006). Another possible mechanism of the suppression of ET-1 level in
renal tissue by PAR2 blockade may involve NO/iNOS pathway. Systemic
administration of PAR2 agonist in vivo in rats andmice causes hypoten-
sion (Cicala et al., 2001; Emilsson et al., 1997). Interestingly, also in
humans in vivo PAR2 agonist causes vasodilatation that is dependent
on NO release and prostanoids (Robin et al., 2003). Thus, we speculate
that PAR2 may regulate ET-1 through modulating NO/iNOS pathway
in sepsis. In our future studies we intend to investigate in more depth
the mechanisms underlying the reversal effects of PAR2 BP on the
elevated levels of renal ET-1 in endotoxemia.
Conclusion
The present study demonstrates that ET-1, TNF-α and iNOS expres-
sions are increased at various time points in renal tissues after LPS ad-
ministration in rats and reports for the first time that blockade of
PAR2 significantly normalizes the elevated renal expressions of TNF-α,
iNOS and ET-1.
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